Penumbra Tops Q2 Revenue, but Merger Costs and Taxes Erode Net Income
PEN sits 45% above its 52-week low of $221.26.
Summary
Penumbra's Q2 revenue of $390M edged past estimates, but net income dropped 23% as merger-related costs and a higher tax rate offset strong sales growth.
Key Events · Earnings and Guidance · PEN
-
Q2 Revenue Beats Consensus
Revenue rose 14.9% to $390.0 million, slightly above the $389 million consensus, with embolization and access up 20% and thrombectomy up 12.5%.
-
Net Income Drops 23%
Net income fell to $34.8 million from $45.3 million a year ago, pressured by $6.9 million in acquisition-related costs and a higher effective tax rate.
-
Gross Margin Improves
Gross margin expanded to 67.9% from 66.0% in Q2 2025, reflecting favorable product mix and operating leverage.
-
Guidance Withdrawn Amid Merger
Penumbra will not provide full-year 2026 guidance or host an earnings call, citing the pending acquisition by Boston Scientific.
Analysis · PEN · Industrial Applications And Services
Penumbra posted a solid top-line beat, with revenue climbing 14.9% to $390 million on the back of 20% growth in embolization and access. Yet net income contracted 23% year-over-year, as $6.9 million in acquisition-related costs tied to the pending Boston Scientific merger and a higher tax rate more than offset the revenue gains. Management is withholding guidance and skipping the earnings call, citing the pending acquisition—a clear sign that closing the deal, not near-term operations, is the priority. For investors, the central question is whether the merger will close as expected; the earnings report itself is a secondary event.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PEN was trading at $319.83 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $221.26 to $362.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.